Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Exclusion Criteria

• •1. Was at risk of imminent death (death expected within 24 hours).
• •2. Received extracorporeal membrane oxygenation (ECMO).
• •3. Had a life-threatening abnormality (cranial, cardiac, thoracic), chromosomal abnormality, congenital diaphragmatic hernia, congenital heart defect (other than patent ductus arteriosus or small atrial septal defect).
• •4. Had been resuscitated requiring chest compressions within 6 hours of receiving INOmax.
• •5. Had Grade IV bilateral intraventricular hemorrhage or periventricular leukomalacia.
• •6. Had active uncontrolled bleeding.
• •7. Had disseminated intravascular coagulopathy.
• •8. Had active seizures while receiving anticonvulsants.
• •9. Experienced prolonged asphyxia with evidence of severe acidosis (pH \< 7.25).
• •10. Received concomitant pulmonary vasodilator therapy (eg, prostacyclin or sildenafil) except when sildenafil was used to wean the participant from INOmax therapy.